Safety and efficacy of etelcalcetide, an intravenous calcimimetic, for up to 52 weeks in hemodialysis patients with secondary hyperparathyroidism: results of a post-marketing surveillance in Japan

BACKGROUND: Etelcalcetide is a second-generation calcimimetic for the management of secondary hyperparathyroidism (SHPT) in patients on dialysis. We performed a post-marketing surveillance (PMS) to obtain information on the safety and efficacy of etelcalcetide in clinical practice in Japan. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Yokoyama, Keitaro, Fukagawa, Masafumi, Shigematsu, Takashi, Akiba, Takashi, Yoshikawa, Ken, Tsuchiya, Akira, Kuwabara, Misato, Akizawa, Tadao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7794109/
https://www.ncbi.nlm.nih.gov/pubmed/32816132
http://dx.doi.org/10.1007/s10157-020-01936-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7794109/
https://www.ncbi.nlm.nih.gov/pubmed/32816132
http://dx.doi.org/10.1007/s10157-020-01936-2

Ejemplares similares